[Pharmacotherapy of alcohol dependence].
Soyka
M
M
Psychiatrische Klinik der Universität München, München. Michael.Soyka@pm-klinik.ch
D000077443:Acamprosate; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000427:Alcohol Deterrents / Q000009:adverse effects / Q000627:therapeutic use; D000437:Alcoholism / Q000534:rehabilitation*; D000553:Ambulatory Care; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D002719:Chlormethiazole / Q000009:adverse effects / Q000627:therapeutic use; D000431:Ethanol / Q000633:toxicity*; D005194:Family Practice; D006801:Humans; D009271:Naltrexone / Q000009:adverse effects / Q000627:therapeutic use; D010343:Patient Admission; D055502:Secondary Prevention; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis / Q000534:rehabilitation*; D013654:Taurine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000427:Alcohol Deterrents; D000927:Anticonvulsants; D002719:Chlormethiazole; D001569:Benzodiazepines; D013654:Taurine; D000431:Ethanol; D009271:Naltrexone; D000077443:Acamprosate